Newsmeme!
Discover News you didn't know existed
SATURDAY Hughley heads to Paramount D.L. Hughley performs at 8 p.m. Saturday at the Paramount Theater in Aurora.
Students, professors and others crammed into Dickinson College’s Stern Center great room Thursday night to witness a debate on the legalization of marijuana in the commonwealth.
FAIRFIELD -- Failure. That word is the title of the first chapter of "Three Cups of Tea," adventurer and activist Greg Mortenson's book about his quest to build a school in a small Pakistani
All calendar items are in El Paso unless otherwise stated. Alcoholics Anonymous, call for details. 562-4081, (505) 589-1058, 757-3327, 595-9940, and 838-6264 (Spanish).
Experts said the new study had all but closed the case: For the brain, remembering is a lot like doing.
BROOKS, Pamela Barlow December 5th, 1943 - August 8th, 2008 Pamela passed peacefully surrounded by her family and friends after a 9 year journey with cancer. Pamela lived her life full-on; she began her journey in Northern England, then continued as a young immigrant bride with child in Ontario, then back to the land on a farm in Cape Breton, then to being an urbanite in Victoria where she was ...
Elizabeth Lurena Whidden of Norwalk, formerly of Weston, died Aug. 14, 2008, at Norwalk Hospital. She was 30. She was born May 1, 1978, in Kingston, N.Y., daughter of Mark Phillips and Libby Schneider Whidden of Providence Forge, Va.
3T MRI is better at detecting and characterizing structural brain abnormalities in patients with focal epilepsy than 1.5T MRI, leading to a better diagnosis and safer treatment of patients, according to a study conducted at the Oregon Health and Science University in Portland, OR.
( American Roentgen Ray Society ) 3T MRI is better at detecting and characterizing structural brain abnormalities in patients with focal epilepsy than 1.5T MRI, leading to a better diagnosis and safer treatment of patients, according to a recent study conducted at the Oregon Health and Science University in Portland, Ore.
NeurAxon, Inc., a developer of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced data from its Phase 2 clinical trial of NXN-188 in patients with migraine. In the study, patients experiencing migraine with aura, which represents over 7 million patients in the US, achieved sustained relief from their headaches, representing a potentially ...
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |